Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors’ reply
Summary No abstract available. Countries: Singapore, South Korea
-
-
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study
Summary Background Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of liver disease cases, and there is a need to better understand future disease burden. We used a modelling framework to forecast the burden of disease of NAFLD and NASH for Canada. Methods We used a Markov model to […]
-
Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
Summary Importance Achievement of the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) by 2030 will require an increase in key services, including harm reduction, HCV screening, and HCV treatment initiatives in member countries. These data are not available for Canada but are important for informing a national HCV elimination strategy. Objective […]
-
Modelling NAFLD disease burden in four Asian regions-2019-2030
Summary Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia-Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. Aims To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are […]
-
Nonalcoholic fatty liver disease burden: Australia, 2019-2030
Summary Background and Aim Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a large and growing proportion of liver disease burden globally. The burden of NAFLD/NASH manifests in increasing levels of advanced liver disease and primary liver cancer in Australia. A Markov model was used to forecast NAFLD burden in Australia through […]
-
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Summary Background Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups have been widely published, but the disease burden in children is poorly understood. Direct-acting antiviral drugs, which are considered to be highly effective curative therapies for HCV, are now approved for paediatric patients as young as 3 years. Reliable prevalence estimates for […]
-
Nonalcoholic fatty liver disease burden – Switzerland 2018-2030
Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term […]
-
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake – a modeling study
Summary Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C (HCV) in Australia. Based on rapid uptake (32,600 people initiated DAA in 2016) we estimated the impact on HCV epidemiology and mortality in Australia and determined if Australia can meet the WHO HCV elimination targets by 2030. Using […]
-
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Summary Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease […]
-
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Summary Background/Aim Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver diseaseburden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods Models were used to estimate NAFLD and NASH disease […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic